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Abstract
Background: HIV-infected adults initiating antiretroviral therapy (ART) in sub-Saharan Africa continue to experience
high rates of morbidity and mortality during the initial months of treatment. Observational studies in high-income
and resource-limited settings indicate that HIV-infected adults with low vitamin D levels may be at increased risk of
mortality, HIV disease progression, and incidence of pulmonary tuberculosis (TB). As a result, vitamin D3 supplementation
may improve survival and treatment outcomes for HIV-infected adults initiating ART.
Methods/Design: The Trial of Vitamins-4 (ToV4) is an individually randomized, double-blind, placebo-controlled trial of
vitamin D3 (cholecalciferol) supplementation conducted among 4000 HIV-infected adults with low vitamin D levels
[25-hydroxyvitamin D (25(OH)D) <30 ng/mL] initiating ART in Dar es Salaam, Tanzania. The two primary aims of the trial
are to determine the effect of a vitamin D3 supplementation regimen on incidence of (1) mortality and (2) pulmonary
TB as compared to a matching placebo regimen. The primary safety outcome of the study is incident hypercalcemia.
The investigational vitamin D3 regimen consists of oral supplements containing 50,000 IU vitamin D3 taken under direct
observation at randomization and once a week for 3 weeks (four doses) followed by daily oral supplements containing
2000 IU vitamin D3 taken at home from the fourth week until trial discharge at 1 year post ART initiation. Trial
participants are followed up at weekly clinic visits during the first month of ART and at monthly clinic visits
thereafter until trial discharge at 1 year post ART initiation. Secondary aims of the trial are to examine the effect
of the vitamin D3 regimen on CD4 T cell reconstitution, incidence of non-TB comorbidities, body mass index
(BMI), depression and anxiety, physical activity, bone health, and immunologic biomarkers.
Discussion: The ToV4 will provide causal evidence on the effect of vitamin D3 supplementation on incidence of
pulmonary TB and mortality among HIV-infected Tanzanian adults initiating ART. The trial will also give insight to whether
vitamin D3 supplementation trials for the prevention of pulmonary TB should be pursued in HIV-uninfected populations.
Trial registration: ClinicalTrials.gov, NCT01798680. Registered on 21 February 2013.
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Background
Access to antiretroviral therapy (ART) coverage has rap-
idly increased in sub-Saharan Africa during the last dec-
ade with over 12 million human immunodeficiency virus
(HIV)-infected individuals on ART in 2015 [1]. In con-
trast to the success in expanding ART access, HIV-
infected adults initiating ART in sub-Saharan Africa
continue to experience significantly higher rates of mor-
bidity and mortality during the initial months of treat-
ment as compared to HIV-infected individuals in high-
income settings [2, 3]. The 1-year mortality rate for
HIV-infected individuals initiating ART in the urban
Dar es Salaam, Tanzania HIV care and treatment pro-
gram is estimated to be 13.1% [4]. As a result, low-cost
interventions are needed to prolong and improve quality
of life for HIV-infected individuals receiving ART in
Tanzania and similar resource-limited settings.
Vitamin D is a potent immunomodulator with effects
on both adaptive and innate immune responses which
may play a prominent role in control of intracellular
pathogens by enhancing cell-mediated immunity, pro-
duction of antimicrobial peptides, and phagocytic activ-
ity of macrophages [5–7]. Accordingly, HIV-infected
individuals with adequate levels of vitamin D may better
control HIV replication and intracellular opportunistic
infections as compared to individuals with suboptimal
vitamin D [8]. Observational cohort studies have exam-
ined the association of vitamin D status with HIV-
related morbidity and mortality in both high-income
and resource-limited settings [9–17]. The largest study
to date in high-income settings was conducted among a
sub-sample of 1985 individuals enrolled in the Euro-
SIDA cohort, which consists of HIV-infected adults from
31 European countries, Israel, and Argentina [11]. The
EuroSIDA vitamin D study determined individuals in the
highest (>20 ng/ml) and middle (12–20 ng/mL) tertiles
of 25-hydroxyvitamin D (25(OH)D) had 44% and 32%
reduced risk of death as compared with individuals in
the lowest tertile (<12 ng/mL), respectively [11]. To the
best of our knowledge, there have been three prospective
cohort studies of vitamin D conducted among HIV-
infected adults in resource-limited settings [13–16]. The
first vitamin D cohort study was conducted by our
group among 884 HIV-infected Tanzanian pregnant
women prior to availability of ART and we determined
women in the highest quintile of 25(OH)D had 42%
lower risk of all-cause mortality as compared with those
in the lowest quintile [13]. In addition, <32 ng/mL
25(OH)D was associated with increased risk of progres-
sion to World Health Organization (WHO) HIV stage 3
or 4 disease and incidence of severe anemia, wasting,
acute upper respiratory infections, and oral thrush [13].
We also more recently conducted a prospective cohort
study of vitamin D among HIV-infected adult men and
women initiating ART in Dar es Salaam, Tanzania [15,
16]. In this study we found individuals with vitamin D
deficiency at ART initiation (25(OH)D levels <20 ng/
mL) had twice the risk of mortality during the first
2 years of treatment as compared to individuals with
vitamin D sufficiency (25(OH)D levels >30 ng/mL) [16].
HIV-infected adults initiating ART with vitamin D suffi-
ciency also had reduced risk of incident pulmonary tu-
berculosis (TB), oral thrush, wasting, and >10% weight
loss [15]. The third observational cohort study was con-
ducted among 398 HIV-infected Ugandan adults receiv-
ing ART, which found individuals with vitamin D
deficiency (<20 ng/mL 25(OH)D) had on average 65
cells/μL lower CD4 T cell counts at 18 months of
follow-up as compared to individuals with vitamin D
sufficiency (>30 ng/mL 25(OH)D). Overall, the observa-
tional evidence suggest HIV-infected individuals with
low levels of vitamin D may be at increased risk of mor-
tality, pulmonary TB, HIV disease progression, have
poorer CD4 T cell reconstitution when on ART. Never-
theless, there are no published randomized controlled
trials of vitamin D supplementation among HIV-infected
adults in resource-limited settings published to date to
determine causal effects.
The potential role of vitamin D in pulmonary TB im-
mune responses has long been acknowledged as over
25 years ago Rook and colleagues published results
showing the active form of vitamin D suppressed prolif-
eration of Mycobacterium tuberculosis (Mtb) [18]. Over
the past few decades, a large number of studies have ex-
amined the role of vitamin D in immune responses, par-
ticularly in macrophage function [6]. A study by Liu and
colleagues found that ligation of macrophage toll-like re-
ceptor 2/1 by Mtb antigen induces expression of the
vitamin D receptor and synthesis of 1,25(OH)2D [19].
Synthesis of 1,25(OH)2D by macrophages can then up-
regulate expression of cathelicidin, which is an anti-
microbial peptide integral for killing Mtb and other
intracellular pathogens [20, 21]. In addition, a landmark
study by Fabri and colleagues determined vitamin D is
required for an interferon-gamma (IFN-γ)-mediated
antimicrobial pathway in macrophages which leads to
autophagy, phagosomal maturation, and other anti-
microbial activities against Mtb [5]. Generally, there is
strong evidence from immunological studies suggesting
that maintaining adequate levels of vitamin D may im-
prove immune responses to TB.
There have also been a similarly large number of epi-
demiologic studies conducted on the relationship of vita-
min D and incidence of pulmonary TB. Numerous case-
control studies have determined individuals with active
TB have significantly lower 25(OH)D and different gen-
etic variants of the vitamin D receptor (VDR) as com-
pared to healthy controls or the general population [22–
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26]. A recent case-control study among HIV-uninfected
and HIV-infected South Africans found TB cases had
about five times the odds of vitamin D deficiency
(25(OH)D <20 ng/mL) as compared to population con-
trols [27]. Nevertheless, these cross-sectional studies are
prone to bias due to reverse causation since increased
immune activation in individuals with active TB may
lead to decreased 25(OH)D levels [6]. Only a few pro-
spective cohort studies, which limit the potential of re-
verse causation, have examined the association of
vitamin D and incidence of TB [15, 28, 29]. In one small
prospective cohort study conducted in Pakistan, house-
hold TB contacts in the lowest tertile 25(OH)D (<7 ng/
mL) had increased risk of developing TB, although these
results are based on only eight incident TB cases [29].
Another small cohort study of TB contacts in Spain de-
termined contacts with low vitamin D (<10 ng/mL
25(OH)D) had increased risk of tuberculin skin test con-
version [28]. We conducted the largest prospective co-
hort study of vitamin D and incidence of TB to date
among HIV-infected Tanzanian adults initiating ART
[15]. In this study we determined individuals with
25(OH)D levels <20 ng/mL at ART initiation had ap-
proximately three times the risk of incident pulmonary
TB as compared to adults with >30 ng/mL and this rela-
tionship persisted after excluding TB cases in the first
2 months of ART to effectively rule out reverse caus-
ation [15]. Overall, there is a growing base of observa-
tional evidence that HIV-infected and HIV-uninfected
individuals with low vitamin D may be at increased risk
of developing pulmonary TB.
Randomized controlled trials of vitamin D treatment
for individuals with pulmonary TB have produced mixed
findings on sputum conversion and other TB treatment
outcomes; however, no randomized controlled trials of
vitamin D have been conducted for prevention of pul-
monary TB disease to the best of our knowledge [30].
One small randomized trial conducted in Mongolia ex-
amined the effect of vitamin D3 supplementation on tu-
berculin skin test conversion among 120 children [31].
In this trial children supplemented with 800 IU vitamin
D3/day had about a 60% reduction in the risk of tuber-
culin skin test conversion during the 6 months of
follow-up as compared to children randomized to pla-
cebo, but the results were not statistically significant
[31]. A major barrier to conducting pulmonary TB pre-
vention trials in the general population is the large sam-
ple size required due to low rates of TB activation (1%
of those with positive tuberculin skin test per year) [32].
Nevertheless, these sample size issues are not insur-
mountable since incident pulmonary TB endpoints are
feasible in trials of HIV-infected populations. TB activa-
tion rates are 7–10% per year in individuals with ad-
vanced HIV disease [8]. As a result, randomized
controlled trials of vitamin D supplementation for TB
prevention among HIV-infected individuals can be used
to inform if larger and more costly trials are needed
among HIV-uninfected populations, including TB
contacts.
Overall, there is a growing biologic and epidemiologic
evidence base which suggests HIV-infected individuals
with low vitamin D levels may have increased risk of in-
cident pulmonary TB disease and mortality; however, no
randomized controlled trials of vitamin D supplementa-
tion have been published to date. In order to provide
much needed causal evidence, we present the protocol
for an ongoing individually randomized, parallel group,
double-blind, placebo-controlled trial of vitamin D3 sup-
plementation conducted among HIV-infected individuals
initiating ART in Dar es Salaam, Tanzania.
Methods/Design
The Trial of Vitamins-4 (ToV4) is an individually ran-
domized, parallel group, double-blind, placebo-
controlled trial of vitamin D3 (cholecalciferol) supple-
mentation among HIV-infected adults initiating ART in
Dar es Salaam, Tanzania (ClinicalTrials.gov identifier
NCT01798680). The trial protocol was developed by col-
laborators at the Harvard T.H. Chan School of Public
Health in the United States and Management and Devel-
opment for Health (MDH) in the United Republic of
Tanzania. The ToV4 protocol diagram is presented in
Fig. 1. The schedule of trial enrollment, interventions,
and assessments is presented in Fig. 2. The first partici-
pant was enrolled in the trial on 24 February 2014 and
enrollment is expected to continue until March 2017
with follow-up data collection continuing until March
2018. This protocol was written following the Standard
Protocol Items: Recommendations for Interventional tri-
als (SPIRIT) checklist (see Additional file 1).
Primary and secondary objectives
The overall goal of ToV4 is to investigate a vitamin D3
as a simple and low-cost intervention to prolong and
improve quality of life for HIV-infected women and men
who are initiating ART. The two primary aims of the
study are to determine the effect of a vitamin D3 supple-
mentation regimen on the hazard of incident (1) mortal-
ity and (2) pulmonary TB as compared to a matching
placebo regimen during the time period of enrollment at
ART initiation to discharge at 1 year of follow-up. The
secondary aims of the trial are to examine the effect of
the vitamin D3 regimen on (a) post-randomization CD4
T cell count as mean difference in cells/μL, (b) incidence
of comorbidities and complications associated with HIV
and/or ART, (c) post-randomization body mass index
(BMI) as mean difference in kg/m2, (d) incidence of
wasting (BMI <18.5 kg/m2) and >10% weight loss from
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baseline, (e) post-randomization depression and anxiety
as mean difference in Hopkins Symptom Checklist
(HSCL) scores, (f ) post-randomization physical activity
as mean difference in metabolic equivalents (METs), (g)
post-randomization bone health biomarkers [parathyroid
hormone (PTH) and alkaline phosphatase (ALP)] as mean
difference in concentrations (h) post-randomization im-
munologic biomarkers [interlukin-2 (IL-2), interlukin-12
(IL-12), interferon-gamma (IFN-γ), and the antimicrobial
peptide cathelicidin] as mean difference in concentrations
and (i) risk of hypercalcemia (albumin-adjusted calcium
>2.6 mmol/L).
Study population
Individuals are eligible for the trial randomization if they
meet all the following inclusion criteria: (a) adult men or
women aged ≥18 years old, (b) HIV-infected, (c) initiat-
ing ART at the time of randomization, (d) have low vita-
min D levels with a 25(OH)D concentration <30 ng/mL
at ART initiation (e) intending to stay in Dar es Salaam
for at least 1 year after enrollment, and (f ) provide writ-
ten informed consent. Exclusion criteria include: (a)
pregnancy (women of childbearing age are required to
have a negative pregnancy test within a month prior to
randomization) and (b) enrolled in any other clinical
trial. During the trial the ART initiation criteria for the
Dar es Salaam HIV treatment program changed from
CD4 T cell count <350 cells/μL or WHO HIV stage 3 or
4 disease to CD4 T cell count <500 cells/μL or WHO
HIV stage 3 or 4 disease in January 2016.
Vitamin D3 and placebo regimens
The investigational vitamin D3 trial regimen consists of
oral supplements containing 50,000 IU vitamin D3 taken
at randomization and once a week for 3 weeks at clinic
visits under direct observation (four doses) followed by
daily oral supplements containing 2000 IU vitamin D3
taken in the home starting at the fourth week until trial
discharge at 1 year post ART initiation. The matching
placebo regimen consists of oral placebo supplements
taken at randomization and once a week for 3 weeks at
clinic visits under direct observation (four doses)
followed by daily oral placebo supplements taken in the
home starting at the fourth week until trial discharge at
1 year post ART initiation.
We decided to use vitamin D3, rather than vitamin D2
(ergocalciferol), since vitamin D3 is more effective in in-
creasing and sustaining levels of circulating 25(OH)D
[33]. In addition, the two-stage vitamin D3 supplementa-
tion regimen was selected in order to quickly and safely
boost 25(OH)D levels with the weekly 50,000 IU supple-
ments followed by maintenance of 25(OH)D levels
thereafter with the daily 2000 IU supplements. The ma-
jority of mortality for HIV-infected individuals initiating
ART in resource-limited settings occurs in the first
months of treatment and as a result boosting 25(OH)D
levels quickly with large doses of vitamin D3 may pro-
duce a larger effect than daily supplements which would
more gradually increase 25(OH)D over time [2]. A ran-
domized trial using a similar two-stage regimen of
weekly 50,000 IU vitamin D3 for 4 weeks followed by
monthly 50,000 IU vitamin D3 maintenance doses of
vitamin D3 among adults with primary hyperparathyr-
oidism found 25(OH)D levels increased 19 ng/mL from
baseline to 6 months and maintained levels up to 1 year
[34]. We expect a similar approximately 20 ng/mL in-
crease in 25(OH)D from randomization to 6 months. In
our trial, we predict nearly all individuals in the vitamin
D treatment arm will obtain 25(OH)D levels >30 ng/mL
and expect no participant to exceed 85 ng/mL based on
the distribution of 25(OH)D in our preliminary observa-
tional cohort study [16]. In terms of safety, vitamin D3
supplements containing 50,000 IU taken weekly have
been found safe and effective in increasing 25(OH)D
among individuals with breast cancer, multiple sclerosis,
and chronic kidney disease [35–37]. Trials of 2000 IU
vitamin D3 supplements taken daily have found the regi-
men maintained or slightly increased 25(OH)D overtime
with very low risk of side effects [38–40].
Fig. 1 Trial of Vitamins-4 (ToV4) flow diagram. 25(OH)D 25-
hydroxyvitamin D, ART antiretroviral therapy, LTFU loss to follow-up,
TB tuberculosis
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Inclusion of a placebo control was determined to be
ethical since it is not known whether the relationship of
serum 25(OH)D with morbidity and mortality is causal
based on evidence from observational cohort studies
and it is also unknown if vitamin D supplementation
starting at ART initiation can increase 25(OH)D levels
during the relevant biological window to have an effect
on mortality, pulmonary TB, and other treatment out-
comes [15, 16]. It is also possible vitamin D supplements
may have a negative effect by slowing CD4 T cell im-
mune reconstitution due to promotion of Th2 re-
sponses, which furthers the principle of equipoise [8,
16]. In addition, a trial of vitamin D supplementation ad-
junct to TB treatment conducted in Guinea-Bissau
found some indication of increased risk of mortality for
TB/HIV co-infected participants in the vitamin D3 arm
as compared with the placebo arm [41].
The vitamin D3 and placebo regimen for ToV4 are
produced in the United States by Tischcon Corp. (Salis-
bury, MD). There is no discernible difference between
vitamin D3 and placebo supplements in appearance or
taste. The regimen bottles for vitamin D3 and placebo
are also identical except for a unique participant ID
label. The weekly 50,000 IU vitamin D3 and matching
placebo supplements are single hard gelatin capsules
containing a light creamy powder which weigh on aver-
age 765 mg. The weekly regimen is stored in bottles
containing five capsules (one extra supplement), which
are pre-labeled with the participant’s study ID. The daily
2000 IU vitamin D3 supplements and placebo supple-
ments are hard gelatin capsules containing white powder
which weigh on average 477 mg. The daily regimen is
stored in bottles containing 35 capsules which are pre-
labeled with the patient ID. The vitamin D3 and placebo
regimens have a shelf-life of 2 years and as a result two
batches are required to complete the trial. In order to
monitor composition of the supplements throughout
their shelf-life, Tishcon Corp. tests a random sample of
capsules for the amount of vitamin D3 contained in each
capsule by high-performance liquid chromatography
(HPLC) at production and then again at the end of the
shelf-life after return shipping from Tanzania. Table 1
presents the content of vitamin D3 and placebo sup-
plements for the first and second regimen batches.
The first batch of vitamin D3 and placebo supple-
ments contained the expected amount of vitamin D3
at production and maintained composition for the
duration of the shelf-life.
Fig. 2 Schedule of enrollment, interventions and assessments (SPIRIT figure). 25(OH)D 25-hydroxyvitamin D
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Sample size
Sample size and power calculations for ToV4 assumed
1:1 randomization to vitamin D3 and placebo arms, a
nominal Type I error rate (alpha) of 0.05 and a 10% loss
to follow-up rate. Due to the possibility of improved
care, increased CD4 T cell thresholds for ART initiation
and expanded use of isoniazid preventive therapy (IPT)
overtime, we selected a trial sample size of 4000 individ-
uals that would provide adequate power for a range of
mortality and pulmonary TB rates. Power for the bino-
mial outcomes of mortality and pulmonary TB were cal-
culated based on a two-sided two-sample test for
proportions. Assuming a total sample size of 4000 indi-
viduals, Table 2 shows the power to detect a range of
relative risks for mortality and pulmonary TB for the
vitamin D3 arm compared with the placebo arm with
varying cumulative incidence of mortality and pulmon-
ary TB in the placebo arm. In terms of the mortality
endpoint, the ToV4 with an expected sample size of
4000 will have excellent power to detect a relative risk of
0.70 or less (≥90% power), even if the 1-year incidence
of mortality in the placebo group decreases to 10% (90%
power). A sample size of 4000 will also have 85% power
to detect a relative risk of 0.75 if the 1-year mortality
rate is 12.5%. This range of detectable effect sizes for
mortality is reasonable based on our preliminary obser-
vational cohort study which found a 50% increase in risk
of mortality among HIV-infected individuals initiating
ART with vitamin D deficiency as compared to suffi-
ciency [16]. The cumulative incidence of pulmonary TB
during the first year of ART among HIV-infected adults
enrolled in ART programs in Africa varies between 5
and 10% [42]. The ToV4 with a sample size of 4000 has
excellent power (>85%) to detect relative risk 0.60 or less
and has good power (>79%) to detect a relative risk of
0.70 if the incidence of pulmonary TB in the placebo
arm is greater than 7.5%. This range of detectable effect
sizes for pulmonary TB is also reasonable given our ob-
servational study of HIV-infected adults initiating ART
determined individuals with vitamin D deficiency had
2.89 (95% CI: 1.31–7.41) times the hazard of incident
pulmonary TB as compared to vitamin D sufficient indi-
viduals [15].
Enrollment and follow-up procedures
Screening procedures
The screening visit for ToV4 is integrated with the
ART eligibility visit of the Dar es Salaam HIV care and
treatment program. At the screening visit, clinic doc-
tors identify HIV-infected adults who are eligible for
ART initiation by WHO disease stage or CD4 T cell
counts and refer these individuals to research nurses
for ToV4 screening procedures. Research nurses assess
inclusion/exclusion criteria for the trial and if eligible
also seek written informed consent for a blood draw to
screen serum 25(OH)D levels. In order to assess preg-
nancy status of potential participants, all females are
asked the date of their last menstrual period and any
woman who has not had their menstrual period in the
previous 6 weeks is given a pregnancy test. Individuals
who meet all eligibility for ToV4 screening and con-
sent for a blood draw have 5 mL of blood collected in
a red-top vacutainer tube for serum 25(OH)D assess-
ment. At the screening visit, all participants receive
treatment of comorbidities per Tanzanian standard of
care and are scheduled for an ART initiation visit in
1–2 weeks in concordance with the HIV treatment
program visit protocol.
Table 1 Vitamin D3 content of trial supplements by batch at production and at end of shelf-life as assessed by high-performance li-
quid chromatography (HPLC)
Batch #1 at production
(December 2013)
Batch #1 at end of shelf-life
(September 2015)
Batch #2 at production
(November 2015)
Batch #2 at end
of shelf-life
50,000 IU Vitamin D3 50,949 IU (101.9%) 48,210 IU (96.4%) 52,325 IU (104.7%) Currently in use
Matching Placebo for 50,000 IU None detected None detected None detected Currently in use
2000 IU Vitamin D3 2076 IU (103.8%) 2103 IU (105%) 2162 IU (108.1%) Currently in use
Matching Placebo for 2000 IU None detected None detected None detected Currently in use
Table 2 Statistical power for a trial sample size of 4000 with 1:1
randomization to vitamin D3 and placebo arms, a nominal Type
I error rate (alpha) of 0.05 and a 10% loss to follow-up rate
Mortality
Relative risk of mortality
Cumulative 1-year incidence
mortality in placebo arm
RR = 0.75 RR = 0.70 RR = 0.65
10% 76% 90% 97%
12.5% 85% 95% 99%
15% 91% 98% 99%
Pulmonary tuberculosis (TB)
Relative risk of pulmonary TB
Cumulative incidence
pulmonary TB in placebo arm
RR = 0.70 RR = 0.65 RR = 0.60
5% 61% 75% 86%
7.5% 79% 90% 97%
10% 90% 97% 99%
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Screening 25(OH)D assessment
Blood samples collected at the screening visit are then
sent to a central laboratory where sera are separated by
centrifugation. 25(OH)D concentration was then manu-
ally assessed with the commercial Immunodiagnostics
(IDS) enzyme immunoassay (EIA) per kit protocols
(IDS, Boldon, UK). Prior to the start of the trial we con-
ducted a validation study of the IDS EIA using sera from
our previous observational cohort of HIV-infected Tan-
zanian men and women initiating ART due to reports of
overestimation of serum 25(OH)D by EIA [16, 43]. The
validation study was conducted at the Boston Children’s
Hospital Laboratory in Boston, MA, USA. In the valid-
ation study 40 randomly selected sera had 25(OH)D
assessed both by the IDS EIA and by high-performance
liquid chromatography tandem mass spectrometry
(HPLC-MS/MS) using an API-5000 (AB Sciex, Foster
City, CA, USA) as the ‘gold standard’ [44]. The IDS EIA
was manually performed per commercial kit instruc-
tions. For HPLC-MS/MS testing, serum samples were
first extracted and ‘cleaned up’ using the Aria-TLX-2
(Thermo Fisher Scientific, Waltham, MA, USA) after
which 50 μL was mixed with acetonitrile containing in-
ternal standard of 25-hydroxyvitamin d6D3. Samples
were then centrifuged and 50 μL of the supernatant was
injected into the Aria-TLX-2, passed through a Cyclone-
P column (Thermo Fisher Scientific), and then eluted
through a Kinetex C column (Phenomenex, Torrance,
CA, USA). The eluate was injected into the API-5000
for atmospheric pressure chemical ionization and passed
through the triple quadrupole mass spectrometer for de-
tection and quantified measurements. This HPLC-MS/
MS method is linear up to 100 ng/mL and sensitive to
1 ng/mL. Figure 3 presents a scatterplot of the validation
study results, which show the IDS EIA linearly overesti-
mated 25(OH)D concentration as compared with the
HPLC-MS/MS. Robust regression determined the line of
best fit was IDS EIA 25(OH)D ng/mL = 10.451+
0.886*HPLC-MS/MS 25(OH)D ng/mL. Accordingly, in
order to enroll individuals with 25(OH)D <30 ng/mL we
set the threshold for trial eligibility with the IDS EIA test
kit to 25(OH)D <37 ng/mL.
Randomization procedures
Individuals screened for 25(OH)D levels return to the
clinic within 1–2 weeks for the trial randomization visit
which is integrated with the ART initiation visit of the
HIV treatment program. At the randomization visit, re-
search nurses inform all screened individuals of their
25(OH)D results. Individuals with 25(OH)D levels
≥30 ng/mL are told they have adequate levels of vitamin
D and are not eligible for trial enrollment. All individ-
uals with 25(OH)D levels <30 ng/mL are informed they
have low vitamin D levels as well as potential sources of
vitamin D (sun exposure, oily fish, eggs, etc.). Research
nurses then re-document all eligibility criteria for indi-
viduals with 25(OH)D <30 ng/mL and seek written in-
formed consent for ToV4 enrollment.
Individuals who consent for ToV4 enrollment are indi-
vidually randomized 1:1 to the vitamin D3 or placebo
arm. Randomization procedures were designed for
complete allocation concealment and blinding of all par-
ticipants, clinic staff, senior research staff, and trial stat-
isticians. Trial arm allocation is performed according to
a computer-generated randomization list of 4000 indi-
viduals with sequence blocks of ten stratified by study
clinic that was generated by a non-study statistician.
Two non-study statisticians will hold the randomization
list codes until completion of primary analyses or until
requested by the Data and Safety Monitoring Board
(DSMB). An independent study pharmacist prepares the
vitamin D3 and placebo regimen by labeling bottles with
Fig. 3 Scatterplot of validation study results comparing 25(OH)D concentration assessed by IDS EIA (y-axis) versus HPLC-MS/MS (x-axis). 25(OH)D
25-hydroxyvitamin D, EIA enzyme immunoassay, HPLC-MS/MS high-performance liquid chromatography tandem mass spectrometry,
IDS Immunodiagnostics
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participant IDs based on the randomization list. At the
randomization visit, allocation concealment is performed
by assigning individuals eligible for trial randomization
to the next available numeric participant ID which
corresponds to a set of pre-labeled regimen bottles
with the same participant ID. As a result, all trial par-
ticipants, research staff, and trial statisticians are not
able to determine the allocated trial arm for any trial
participant or identify trial participants who are on
the same trial arm.
At the randomization visit, all study participants re-
ceive a full clinical examination from study physicians,
and have HIV disease stage assessed according to the
WHO criteria [45]. All comorbidities are treated per
Tanzanian standard of care. Nurses also administer a
standardized questionnaire to collect information on
sociodemographics, reported symptoms during the last
30 days (fever, cough, etc), depression, anxiety, social
support, and physical activity. Nurses also collect an-
thropometric measurements including height, weight,
and mid-upper arm circumference. Participants are also
asked for cell phone numbers and location of their
home for follow-up visits, given the participant pro-
vides written informed consent for phone and home
contact with study staff. At the end of the
randomization visit, research nurses directly observe
the participant taking the first supplement of the
weekly regimen. The weekly regimen bottles remain in
the clinic for all participants.
Follow-up clinic visit procedures
All participants are actively followed at weekly clinic
visits for 3 weeks (week 1, 2, 3) followed by monthly
clinic visits at starting at the fourth week until 12 months
post ART initiation. At 12 months, participants are dis-
charged from the trial and continue to receive standard
treatment within the HIV care and treatment program
but are not followed by research staff. At all clinic visits
research nurses administer a questionnaire on symptoms
reported within the last 30 days and collect anthropo-
metric measurements including weight and mid-upper
arm circumference. At the 6-month and 12-month visit
the baseline questionnaire on sociodemographic, depres-
sion, anxiety, social support, and physical activity is re-
administered. Physicians also perform a full clinical
examination, assess WHO HIV disease stage, and treat
all comorbidities in accordance to Tanzanian standard
of care at all study visits. At week 1, week 2, and week
3 clinic visits, nurses directly observe the participant
taking the trial supplement in study clinics. At the
fourth week and at monthly visits thereafter until trial
discharge at 12 months, participants are given regimen
bottles containing 35 trial supplements to be taken
daily in the home.
Primary and secondary outcome assessment
Vital status assessment
Participants who do not come for their scheduled clinic
appointments are contacted via cell phone and/or visited
at home to assess vital status. Participants that are
reached by phone or in the home are asked to come to
the clinic if the participant is physically able to do so.
For patients who traveled out of Dar es Salaam, we
maintain contact via cell phone or with neighbors and
relatives to collect information on the vital status of the
participant. For participants who are confirmed to have
died we administer a standardized verbal autopsy to rel-
atives or individuals present around the time of death to
assign a cause of death. Participants that die in a
health facility also have events before and at the time
of death transcribed from hospital records. Two se-
niors HIV clinicians utilize the verbal autopsy data
and hospital records to establish a cause of death by
consensus. A third senior clinic serves as the tie-
breaker for deaths for which the first two clinicians
cannot reach consensus.
Pulmonary TB assessment
All participants presenting with any of the following five
clinical signs and symptoms at any study visit are con-
sidered pulmonary TB suspects per the Ministry of
Health of Tanzania protocol: cough for 2 weeks or more,
fever, 3 kg weight loss in 1 month or noticeable weight
loss for new patients, night sweats, or hemoptysis. All
TB suspects provide a spot sputum specimen at the
clinic visit symptoms were noted and are given a sputum
container for collection of early morning sputum before
a second visit the next weekday. A third spot specimen
is then collected under supervision by a nurse at the sec-
ond clinic visit. The sputum smears are prepared and
stained using Ziehl-Nielsen technique and examined for
acid-fast bacilli (AFB) by trained health laboratory tech-
nologists who grade the smears on an ordinal scale fol-
lowing standard guidelines of the International Union
Against Tuberculosis and Lung disease [46]. All TB sus-
pects also receive a chest X-ray. During the trial the
GeneXpert System (Cepheid, Sunnyvale, CA, USA)
which uses the cartridge-based Xpert MTB/RIF (Xpert)
assay became available for TB testing at three of the four
study clinics. Participants who are sputum AFB negative
for whom TB is still suspected are tested by GeneXpert
for detection of Mtb. DNA. According to Tanzanian na-
tional guidelines, pulmonary TB diagnosis is made when
at least one sputum smear is positive for AFB, GeneX-
pert detects Mtb DNA, or when there are radiological
features suggestive of TB in the presence of constitu-
tional TB symptoms. Patients start TB treatment on
same the day of diagnosis.
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Hypercalcemia assessment
All participants have serum calcium and albumin
assessed at baseline, 1, 6 and 12 months. Serum calcium
and albumin concentrations are assessed with the Roche
Cobas Integra 400 Plus (Roche Diagnostics, Basel,
Switzerland). Albumin-adjusted serum calcium concen-
trations are then calculated using the following equation:
calcium (mg/dL) = total calcium (mg/dL) + 0.8 × [4 − al-
bumin (g/dL)] [47]. Any participants with above the nor-
mal physiologic range of albumin-adjusted calcium
(>2.6 mmol/L) are diagnosed with hypercalcemia, dis-
continue their trial regimen for the duration of the trial
and are given appropriate clinical management. Individ-
uals with hypercalcemia continue to be followed up until
discharge of the trial and resolution of hypercalcemia. In
addition participants are monitored at all clinic visits by
study physicians for symptoms of hypercalcemia includ-
ing: nausea, vomiting, excessive thirst, anorexia, symp-
toms of kidney stones, and confusion. If any of these
symptoms are reported and there is no other suspected
cause, study clinicians order calcium and albumin test-
ing. At this point participants with suspected hypercalce-
mia stop their randomized treatment regimen until
calcium testing results are returned. If albumin-adjusted
calcium levels are normal for hypercalcemia suspects,
the patient is allowed to re-start the regimen under dis-
cretion of study physicians. Hypercalcemia suspects with
albumin-adjusted calcium >2.6 mmol/L discontinue
their trial regimen for duration of the trial and are given
appropriate clinical management.
Laboratory investigations
All participants have CD4 T cell counts assessed at or
before the ToV4 screening/ART eligibility visit and then
every 6 months after ART initiation. Hemoglobin is also
measured at the ToV4 screening/ART eligibility visit. In
order to examine the effect of the vitamin D3 regimen
on bone health, we will measure PTH and ALP at base-
line, 1, 6, and 12 months for a random sample of 800 in-
dividuals (20%). We will also assess the effect of vitamin
D3 on host immune response through measurement of
IL-2, IL-12, IFN-γ, and the antimicrobial peptide catheli-
cidin in 800 (20%) randomly selected individuals at base-
line, 1, 6, and 12 months.
Compliance assessment
Any trial requires a high degree of compliance with ex-
perimental regimens as non-compliance can bias results
and decrease the statistical power of a study. The best
way to ensure full compliance is to observe each partici-
pant ingesting treatment. In ToV4 research nurses dir-
ectly monitor subjects taking the weekly trial
supplements (randomization, week 1, week 2, week 3),
but this type of monitoring is not practical for the
subsequent daily supplements taken in the home (week
4 to month 12). In order to promote adherence during
the daily regimen period, all participants are encouraged
to use the daily supplements at the same time every day,
to put the bottle in a visible place, and identify an adher-
ence assistant who would remind her/him to take the
supplement. Compliance with the daily ToV4 supple-
ments will be assessed three ways: (a) direct questioning
about use of the supplements in the previous 24 hours
and 2 weeks, (b) pill count from returned daily regimen
bottles, and (c) biochemical assessment of 25(OH)D in a
subset of participants longitudinally at randomization, 1,
6, and 12 months.
Standard of care
All study participants are provided with HIV care and
treatment that adhere to Tanzanian national guidelines.
During the trial the ART initiation criteria within the
Dar es Salaam HIV treatment program changed from
CD4 T cell count <350 cells/μL or WHO HIV stage 3 or
4 disease to CD4 T cell count <500 cells/μL or WHO
HIV stage 3 or 4 disease in January 2016. Per Tanzanian
guidelines, zidovudine, lamivudine, and efavirenz are the
choice first-line regimen with tenofovir, nevirapine, and
stavudine as back-up drugs. The standard visit schedule
for patients on ART is clinic visits at 2 weeks and
1 month post-initiation with monthly thereafter. Patients
who are stable after 6 months of ART are eligible receive
a 2-month supply of ART with a subsequent scheduled
clinic visit at corresponding 2-month intervals. CD4 T
cell counts are assessed at the ART eligibility visit and
every 6 months after ART initiation. During the trial
HIV viral load testing became available as standard of
care with assessment every 6 months after ART initi-
ation. Prophylaxis for opportunistic infections is pro-
vided in line with the Tanzanian HIV treatment
guidelines. Participants receive co-trimoxazole prophy-
laxis if CD4 cell count is <200 cells/μL. All participants
diagnosed with TB are treated according to the WHO-
approved guidelines of the National Tuberculosis and
Leprosy Program (NTLP) in Tanzania. All TB patients
receive directly observed therapy (DOT) with a 6-month
short course regimen consisting of a 2-month intensive
phase of daily rifampicin/isoniazid/pyrazinamide/etham-
butol (RHZE) combination tablets, followed by a 4-
month continuation phase of daily rifampicin and isonia-
zid (RH) combination tablets. Sputa from smear-positive
TB patients is collected and examined at 0, 2 and
5 months and at any other time if recurrence of TB is
suspected. If the direct sputum smear is negative at the
end of 2 months, the continuation phase is started and if
a smear is still positive at 3 months the patient is
checked for multi-drug resistance. Treatment failures
and relapses are treated with an 8-month re-treatment
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regimen containing rifampicin throughout, with the in-
tensive period with RHZE and streptomycin injection
continuing for 3 months. Psychological and nutritional
support is also provided as standard of care.
Statistical analysis plan
An intent-to-treat analysis will be used as the primary
analytic strategy for all analyses. The primary efficacy
trial endpoints for this trial are (1) death and (2) incident
pulmonary TB. The primary safety endpoint is hypercal-
cemia (albumin-adjusted calcium >2.6 mmol/L). We will
use the use the log-rank test to test the differences in
the incidence rates of death and pulmonary TB between
the treatment arms, and use the Fisher’s exact test to test
differences in proportion of participants with incident
hypercalcemia.
The secondary endpoints for the study include: (a)
post-randomization CD4 T cell count, (b) incidence of
comorbidities and complications associated with HIV
and/or ART, (c) post-randomization BMI, (d) incidence
of wasting (BMI <18.5 kg/m2) and >10% weight loss
from baseline, (e) post-randomization depression and
anxiety scores as assessed by the Hopkins Symptom
Checklist (HSCL), (f ) post-randomization physical activ-
ity as measured by METs, (g) post-randomization bone
health biomarker levels (PTH and ALP) and (h) post-
randomization immunologic biomarker levels (IL-2, IL-
12, IFN-γ, and cathelicidin). We will use linear mixed-
effects models with a random intercept, a compound
symmetric covariance structure, and robust standard er-
rors to assess mean differences between baseline and
post-randomization levels of CD4 T cell count, BMI,
METs, 25(OH)D, PTH, ALP, IL-2, IL-12, IFN-γ, and
cathelicidin by randomization group. Linear mixed-
effects models will lead to robust inference for the fixed
effects even if the covariance structure is misspecified.
Linear mixed-effects models will also account for
within-subject correlation, and accommodate varying
number and timing of measurements per participant
over time. We will use a generalized linear mixed model
with random intercept, a compound symmetric covari-
ance structure, and robust standard errors to assess dif-
ferences in the incidence of comorbidities and
complications associated with HIV and/or ART which
are repeatable binomial events. The log-rank test will be
used to assess differences in the incidence rates of wast-
ing and >10% weight loss between the treatment arms.
We will also examine effect modification of any treat-
ment effect by pre-defined baseline variables: 25(OH)D
concentration, sex, age, BMI, CD4 T cell count,
hemoglobin concentration, WHO HIV disease stage, pul-
monary TB, receipt of isoniazid preventive therapy, ART
regimen, and trial regimen compliance. To assess the stat-
istical significance of each interaction, we will use the
likelihood ratio test for risk-ratio homogeneity in the mor-
tality, pulmonary TB, and hypercalcemia analyses and the
score test in the linear mixed-effects and generalized lin-
ear mixed models for longitudinal secondary outcomes.
Discussion
Antiretroviral therapy coverage is rapidly expanding glo-
bally and treatment programs are in need of interventions
to prolong and improve the quality of life for HIV-
infected individuals in resource-limited settings, especially
during the initial months of treatment [2, 3]. Vitamin D3
supplementation may be an effective ART adjunct inter-
vention since vitamin D deficiency is common among
HIV-infected individuals, ART can further reduce vitamin
D levels by altering vitamin D metabolism, multiple obser-
vational cohort studies have determined low vitamin D
levels are associated with increased risk of mortality, pul-
monary TB, and disease progression among HIV-infected
individuals, and vitamin D3 supplements are known to be
effective and safe in improving vitamin D status [6, 8, 11,
15, 16, 34, 37]. Based on this rationale, the ToV4 was de-
signed to establish the causal effect vitamin D3 supple-
mentation on mortality and incidence of pulmonary TB
among HIV-infected adults initiating ART in Dar es Sa-
laam, Tanzania. A search of clinicaltrials.gov determined
the only other clinical trial of vitamin D3 among HIV-
infected individuals with mortality or morbidity outcomes
listed as primary or secondary outcomes is an ongoing
study called the “Trial of Vitamin D in HIV Progression,
Birth Outcomes, and Child Health” (NCT02305927). This
ongoing trial is also conducted by our research group and
is a randomized, double-blind, placebo-controlled trial of
vitamin D3 supplementation among HIV-infected preg-
nant women in Dar es Salaam, Tanzania. Accordingly, the
ToV4 will likely be the first randomized trial to determine
the effect of vitamin D3 supplementation on mortality and
morbidity outcomes among HIV-infected adult men and
non-pregnant women.
The study population of the ToV4 was purposely de-
fined by inclusion and exclusion criteria to select a
population that may have significant benefit from
vitamin D3 supplementation but also allow for
generalizability of the findings. In the trial we only enroll
HIV-infected adults initiating ART with 25(OH)D levels
<30 ng/mL and exclude individuals with ≥30 ng/mL
from randomization procedures. The 25(OH)D inclusion
criteria was based on our observational cohort study of
HIV-infected adults initiating ART in Tanzania which
suggested there is likely little to no benefit to obtaining
25(OH)D levels >30 ng/mL in terms of mortality and
pulmonary TB in our study population [15, 16]. The re-
striction of the trial population to individuals <30 ng/mL
25(OH)D also assists with translation of the findings as
HIV programs in similar settings will be able estimate the
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potential impact of implementing vitamin D3 supplemen-
tation based on their local prevalence of 25(OH)D
<30 ng/mL. We also tried to maintain the generalizability
of our findings by defining the study population as adults
initiating ART broadly and did not restrict the study
population by CD4 T cell and WHO disease stage criteria.
HIV treatment programs in Tanzania and sub-Saharan Af-
rica are moving from using a <350 to a <500 CD4 T cells/
μL threshold for ART initiation based on WHO guidelines
[48]. As we expected, the Dar es Salaam HIV treatment
program changed ART initiation guidelines from <350 to
a <500 CD4 T cells/μL threshold to a ‘test-and-treat’ strat-
egy during the trial and as a result the general ToV4
population of adults initiating ART became on average
healthier over the course of the trial as the new guideline
were gradually implemented. Nevertheless, the slight de-
crease in power due to lower event rates is outweighed by
the need for our trial to reflect the population of adults
initiating ART for possible implementation of vitamin D3
supplementation in the treatment program. The ToV4
DSMB reviews event rates every 6 months and will rec-
ommend any necessary changes to the trial sample size to
maintain statistical power. Overall, the ToV4 study popu-
lation was carefully designed to include individuals who
may experience the greatest benefits of vitamin D3 supple-
mentation, but will also preserve the generalizability and
potential ability to translate the findings into practice in
Dar es Salaam and similar HIV treatment programs.
Overall, the ToV4 will provide causal evidence if vitamin
D3 should be considered as an ART adjunct intervention
to reduce pulmonary TB and mortality among HIV-
infected adults initiating treatment. The trial will also pro-
vide evidence for the effect of vitamin D3 supplementation
on a wide range of secondary outcomes including: CD4 T
cell reconstitution, non-pulmonary TB comorbidities and
complications associated with HIV and/or ART, bone
health, immunologic biomarkers, weight gain, depression
and anxiety, physical activity, and incidence of hypercalce-
mia. The results of the trial are likely generalizable to
HIV-infected adults with low vitamin D who are initiating
ART in similar resource-limited settings and the trial find-
ings will also inform whether larger vitamin D3 supple-
mentation trials for the prevention of TB in HIV-
uninfected populations should be pursued.
Trial status
Trial enrollment started on 24 February 2014 and re-
cruitment is ongoing as of 26 January 2017.
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